• Publications
  • Influence
Prolactin release after remoxipride by an integrated pharmacokinetic-pharmacodynamic model with intra- and interindividual aspects.
An integrated pharmacokinetic-pharmacodynamic model is suggested for remoxipride and its effect on prolactin (PRL) release acting by preventing the inhibitory effect of dopamine D2 receptors in theExpand
  • 48
  • 5
Pharmacokinetics of Raclopride Formulations
SummaryThe pharmacokinetic and pharmacodynamic properties of raclopride, a new antipsychotic, were investigated in 16 healthy men. Single 4mg doses were administered as intravenous infusion, oralExpand
  • 11
Remoxipride: pharmacokinetics and effect on plasma prolactin.
1. The pharmacokinetics of remoxipride, a new neuroleptic, were investigated in 15 healthy subjects after an intravenous infusion of 50 mg, an intramuscular injection of 100 mg and afterExpand
  • 16
The pharmacokinetics of remoxipride and metabolites in patients with various degrees of renal function.
1. The pharmacokinetics of remoxipride, a new neuroleptic, were investigated in an open study with three parallel groups. Twenty-one patients with severely impaired (ClCr < 25 ml min-1), moderatelyExpand
  • 10
Influence of the dosing interval on prolactin release after remoxipride.
1. The prolactin response following administration of the D2-dopamine receptor antagonist remoxipride was studied in eight healthy male volunteers. The purpose of the study was to investigate theExpand
  • 13
Influence of rate of administration of raclopride on akathisia and prolactin response
The D2-dopamine receptor antagonist raclopride was administered to eight healthy male subjects, who had previously experienced akathisia following antipsychotic drugs. The influence of administrationExpand
  • 6
CLINICAL PHARMACOKINETICS OF REMOXIPRIDE
The clinical pharmacokinetics of remoxipride, a pure enantiomer, have been studied in healthy volunteers and patients. After oral administration the drug is rapidly and almost completely absorbedExpand
  • 2
An open study of tolerability and pharmacokinetics of raclopride extended release capsules in psychiatric patients: a Canadian study.
The tolerability and pharmacokinetics of raclopride extended release (ER) capsules have been evaluated after a single oral dose and at steady state, with 3 different daily doses in 4 male patientsExpand
  • 3
An open study of the pharmacokinetics and the tolerability of raclopride extended release capsules in psychiatric patients
Following a 4–7 day drug-free washout period, eight male inpatients took an extended-release (ER) formulation of raclopride. After the initial 8 mg dose on day 1 of the study, repeated plasma samplesExpand
  • 1
Pharmacokinetics and pharmacodynamics of the neuroleptics remoxipride and raclopride - with special emphasis on prolactin response
Pharmacokinetics and pharmacodynamics of the neuroleptics remoxipride and raclopride - with special emphasis on prolactin response